The Experts below are selected from a list of 33 Experts worldwide ranked by ideXlab platform
Jean-marc Payrat - One of the best experts on this subject based on the ideXlab platform.
-
Stability of blood coagulation factors and inhibitors in blood drawn into half-strength citrate anticoagulant
Vox sanguinis, 1996Co-Authors: A.-m. Suontaka, Claes F. Högman, Olof Åkerblom, M. Blombäck, Lars Eriksson, Jean-marc PayratAbstract:Drawing of blood into a citrate-phosphate-dextrose (CPD) solution with a reduced citrate concentration has been shown to improve the maintenance of coagulation factor VIII (F VIII) in plasma and to give possibilities to improve Erythrocyte Preservation. We studied the quality of plasma obtained from whole blood drawn under continuous mixing into CPD in which the citrate concentration was reduced by 50% (0.5CPD). The blood was stored at room temperature for 8 h before component preparation. We confirmed improved stability of F VIII by 0.5CPD. We found no clinically significant changes in inhibitors to the coagulation and kallikrein systems, and no signs of activation of these systems, during the 8-hour holding time. In control blood drawn into CPD, F VIII and coagulation factor IX decreased by 0.09 IU/ml (8%) and 0.07 U/ml (7%), respectively, otherwise we found no significant differences between 0.5CPD plasma and CPD plasma.
A.-m. Suontaka - One of the best experts on this subject based on the ideXlab platform.
-
Stability of blood coagulation factors and inhibitors in blood drawn into half-strength citrate anticoagulant
Vox sanguinis, 1996Co-Authors: A.-m. Suontaka, Claes F. Högman, Olof Åkerblom, M. Blombäck, Lars Eriksson, Jean-marc PayratAbstract:Drawing of blood into a citrate-phosphate-dextrose (CPD) solution with a reduced citrate concentration has been shown to improve the maintenance of coagulation factor VIII (F VIII) in plasma and to give possibilities to improve Erythrocyte Preservation. We studied the quality of plasma obtained from whole blood drawn under continuous mixing into CPD in which the citrate concentration was reduced by 50% (0.5CPD). The blood was stored at room temperature for 8 h before component preparation. We confirmed improved stability of F VIII by 0.5CPD. We found no clinically significant changes in inhibitors to the coagulation and kallikrein systems, and no signs of activation of these systems, during the 8-hour holding time. In control blood drawn into CPD, F VIII and coagulation factor IX decreased by 0.09 IU/ml (8%) and 0.07 U/ml (7%), respectively, otherwise we found no significant differences between 0.5CPD plasma and CPD plasma.
R. Weinstein - One of the best experts on this subject based on the ideXlab platform.
-
Advances in Erythrocyte Preservation and hemoglobin substitutes.
Current opinion in hematology, 1994Co-Authors: Raymond P. Goodrich, R. WeinsteinAbstract:The desirability of extending the therapeutic benefits of Erythrocyte transfusions beyond the currently available options is well established. Extended frozen storage of rare blood types, hemoglobin-based or artificial blood substitutes for treatment of short-term deficits in oxygen-carrying capacity, novel approaches to tissue oxygenation for cancer therapy, and efficient storage and availability of Erythrocytes in military field installations are all potential applications of ongoing research and development efforts. This review explains the need for improvement in Erythrocyte storage and development of blood substitutes, the current problems in the field, and the progress made toward solving these problems in the past year.
M. Blombäck - One of the best experts on this subject based on the ideXlab platform.
-
Stability of blood coagulation factors and inhibitors in blood drawn into half-strength citrate anticoagulant
Vox sanguinis, 1996Co-Authors: A.-m. Suontaka, Claes F. Högman, Olof Åkerblom, M. Blombäck, Lars Eriksson, Jean-marc PayratAbstract:Drawing of blood into a citrate-phosphate-dextrose (CPD) solution with a reduced citrate concentration has been shown to improve the maintenance of coagulation factor VIII (F VIII) in plasma and to give possibilities to improve Erythrocyte Preservation. We studied the quality of plasma obtained from whole blood drawn under continuous mixing into CPD in which the citrate concentration was reduced by 50% (0.5CPD). The blood was stored at room temperature for 8 h before component preparation. We confirmed improved stability of F VIII by 0.5CPD. We found no clinically significant changes in inhibitors to the coagulation and kallikrein systems, and no signs of activation of these systems, during the 8-hour holding time. In control blood drawn into CPD, F VIII and coagulation factor IX decreased by 0.09 IU/ml (8%) and 0.07 U/ml (7%), respectively, otherwise we found no significant differences between 0.5CPD plasma and CPD plasma.
Claes F. Högman - One of the best experts on this subject based on the ideXlab platform.
-
Stability of blood coagulation factors and inhibitors in blood drawn into half-strength citrate anticoagulant
Vox sanguinis, 1996Co-Authors: A.-m. Suontaka, Claes F. Högman, Olof Åkerblom, M. Blombäck, Lars Eriksson, Jean-marc PayratAbstract:Drawing of blood into a citrate-phosphate-dextrose (CPD) solution with a reduced citrate concentration has been shown to improve the maintenance of coagulation factor VIII (F VIII) in plasma and to give possibilities to improve Erythrocyte Preservation. We studied the quality of plasma obtained from whole blood drawn under continuous mixing into CPD in which the citrate concentration was reduced by 50% (0.5CPD). The blood was stored at room temperature for 8 h before component preparation. We confirmed improved stability of F VIII by 0.5CPD. We found no clinically significant changes in inhibitors to the coagulation and kallikrein systems, and no signs of activation of these systems, during the 8-hour holding time. In control blood drawn into CPD, F VIII and coagulation factor IX decreased by 0.09 IU/ml (8%) and 0.07 U/ml (7%), respectively, otherwise we found no significant differences between 0.5CPD plasma and CPD plasma.